Europe Unlicensed Specials Therapeutic Areas and Patient Groups

Why Patient Need Rather Than Therapy Area Drives Special Orders

Demand for unlicensed specials is created at the level of the individual patient. A licensed product exists for the condition, but it may be unsuitable for this patient because of age, swallowing ability, body size, a combination of conditions or an intolerance to an ingredient. That is why patient group matters as much as therapeutic area in the Europe unlicensed specials market.

The full report therefore uses two dimensions side by side. Therapeutic area has twelve categories: neurology, oncology, cardiology, endocrinology, gastroenterology, infectious diseases, pain management, respiratory diseases, rare diseases, pediatrics, geriatrics and psychiatry. Patient group has six: pediatric, adult, elderly, dysphagia patients, oncology patients and rare disease patients.

Two of the therapeutic areas, pediatrics and geriatrics, are really patient groups, which shows how the source itself mixes the two logics. Reading them together is more informative than reading either alone, because a pediatric patient with a neurological condition creates a very different order from an adult with the same diagnosis.

From a supplier's perspective this means demand cannot be forecast from therapy-area prevalence alone. A therapy area with a very large patient population may generate few special orders because licensed products serve most of it, whereas a smaller area with specific formulation gaps may generate many.

This page describes the demand groups as market segments only. It makes no statement about the clinical use, safety or effectiveness of any medicine for any patient.

The practical effect is that a supplier's portfolio planning starts with patient groups and works back to formulations. A catalogue built around a therapy area would miss the many cross-cutting requests, such as a liquid form for an elderly patient with a swallowing difficulty, that arise in every area.

Pediatric Patients and Oral Liquid Demand

Pediatric patients are the single most important patient group in the unlicensed specials category. Children need doses that scale with body size, formulations they can swallow and flavours they will accept, and few licensed medicines are presented in a way that meets all three needs.

The result is a persistent demand for oral liquids in strengths and concentrations that are not marketed. Pediatric hospitals and high pediatric prescribing regions are identified in the demand mapping chapters of the report as priority buyer groups for this reason.

Pediatric demand has several commercial features. Orders are frequent and repeated, because children are often kept on the same specification for long periods. Dose adjustments as the child grows may require changes to concentration or presentation, and dosage limitations are named among the stakeholder pain points in the full report.

Pediatric shortages are also identified as an area of untapped opportunity in the competitive chapters. Where a product is discontinued or becomes unavailable, there may be no obvious replacement for a young patient, and suppliers that can develop a replacement liquid quickly are well placed.

For suppliers, the group rewards stability of supply and a broad catalogue of strengths, and it favours manufacturers with oral liquid expertise. It also gives hospital pharmacy teams a reason to build long-term relationships rather than buying ad hoc, which is one reason why contract value bands in the full report include regional framework contracts.

Hospital pharmacy teams often hold their own knowledge of which pediatric strengths are requested most. Suppliers that engage with that knowledge, and that retain the products with the most reliable repeat demand even when volumes are modest, build the kind of relationships that lead to inclusion in regional frameworks.

Seasonality is a secondary factor. Respiratory and infectious disease presentations rise in the colder months in hospital pediatric units, and suppliers of oral liquids plan stock holding around these periods rather than waiting for orders to arrive.

Elderly and Dysphagia Patients

Elderly patients and dysphagia patients are related but not identical groups. Dysphagia refers to difficulty in swallowing, which may affect people of any age but is more common in older adults and in those with certain neurological or oncology-related conditions. In the report it appears as its own patient group because the formulation need is specific.

For these patients, liquid, dispersible and easier-to-swallow presentations are commonly requested in place of tablets and capsules. Dysphagia treatment gaps are listed among the stakeholder pain points, which indicates that buyers perceive the licensed range as incomplete for this group.

Geriatric demand is broader. Older patients often take several medicines at once, may be in care homes or receive homecare, and may need changes in presentation as their ability to swallow changes. This links the group to the homecare and community prescribing settings discussed in the report.

Commercially, these groups are growing in importance because of ageing populations across Europe. High aging-population regions are one of the four geographic demand maps in the full report, which indicates that buyers and suppliers see location of older patients as a driver of regional demand.

The supplier response is to extend oral liquid and dispersible ranges and to provide products that suit administration by carers and by feeding tube. These service-oriented additions are often valued as highly as the product itself, particularly in homecare.

Carers and care homes add a further dimension. The person administering the medicine may not be the patient, and presentation, measuring devices and labelling that suit carers are part of what makes a special practical, which is why service features often accompany the product in this group.

Oncology and Rare Disease Patients

Oncology patients and rare disease patients generate lower volumes of more specialised orders. Oncology treatment often involves individualised regimens, supportive medicines in specific forms and sterile preparations, and treatment centres are a named customer segment in the full report.

Rare disease patients are defined by small populations. For many rare conditions there is no licensed presentation in a form suitable for the patient, or the licensed product is available only through specific access programmes, so special manufacture and named patient supply are the practical options.

Because volumes are small, these groups are served by a different set of suppliers from the oral liquid mass of demand. They tend to rely on manufacturers able to make very small batches, on sterile capability and on import specialists, and the choice of route described under the oral liquid and other product types is shaped by the formulation each patient needs.

The report identifies both oncology formulations and rare disease formulations as competitive untapped opportunity mapping, meaning areas in which the current supplier set is judged to leave need unmet. The commercial attraction is that customers in these areas value reliability and clinical support, which are named vendor selection criteria, over cost.

The same features create challenges. Small volumes make unit costs high, product discontinuation is a recurring risk, and a supplier must be willing to hold stock for patients who may need it only occasionally.

A further feature of these groups is that demand arrives through a small number of specialist centres, so a single centre's decision to move supplier can change a product's volume sharply. Suppliers therefore treat relationships with clinical teams in these centres as strategically important.

Because treatment pathways in oncology and rare disease change as new therapies are introduced, suppliers in these groups keep a watching brief on developments in treatment, and may need to retire or adapt products when a licensed alternative appears.

Therapeutic Areas from Neurology to Psychiatry

Across the twelve therapeutic areas, special orders concentrate where patients are commonly managed with oral medicines that are available only as solids, where treatment is long-term and where patients' ability to take standard formulations is variable. Neurology, cardiology, endocrinology, gastroenterology and psychiatry fit this description.

Neurology includes patients who may have swallowing difficulty or need feeding-tube administration, and psychiatry includes long-term oral treatment in a variety of settings. Cardiology and endocrinology involve long-term medicines in patients of all ages, and gastroenterology includes both pediatric and adult patients with specific formulation needs.

Infectious diseases and respiratory diseases generate demand mainly through pediatric patients and through shortages of licensed products, while pain management generates it through presentations adapted for patients who cannot take standard tablets. Oncology and rare diseases are discussed above.

Looking across these areas it is clear that no single therapy area dominates the category, which is one reason why a supplier's portfolio breadth is a competitive measure, and why the settings in which these patients are managed, covered under the settings where these patients are prescribed for, are often a more reliable guide to demand than the therapeutic label.

The full report maps each therapeutic area to product type and prescription setting, allowing readers to see for example that pediatric neurology orders arrive mainly through hospital prescribing, while geriatric demand arrives through community and homecare channels.

The therapeutic area view is also useful to suppliers deciding where to extend portfolios, because adjacent products within one area are often prescribed by the same clinicians and purchased through the same hospital departments, which lowers the cost of reaching new customers.

Pain management and respiratory disease also illustrate how a therapy area can appear in both the hospital and community settings, with the patient's own circumstances rather than the diagnosis determining which route is followed.

How Patient Groups Map to Products and Channels

Each patient group corresponds to a typical set of product types, prescription settings and channels. Pediatric patients map to oral liquids and to hospital and pediatric hospital prescribing. Elderly and dysphagia patients map to oral liquids and dispersible forms, supplied increasingly through community prescribing and homecare.

Oncology patients map to sterile and oral specials delivered through specialist treatment centres and oncology centres, and rare disease patients map to small-volume special manufacture and named patient imports through specialist clinics. Adult patients, as the broadest group, map across all product types.

This pattern means that supplier choices about product type and channel are, in effect, choices about patient groups. A manufacturer that concentrates on oral liquids and hospital pharmacy is primarily serving pediatric and elderly patients, while one that invests in sterile capability and specialist centres is primarily serving oncology and rare disease patients.

Buyers can use the same map to anticipate shortages. When a licensed product used by a given patient group is discontinued, the alternatives will be drawn from the same product types and routes, and the supplier base for that group is relatively predictable.

Procurement behaviour is also tied to group. Medicine shortage response and named patient prescribing are the buying behaviours most associated with rare disease and oncology, therapeutic substitution with elderly and adult groups, and procurement urgency with pediatric patients whose treatment cannot be delayed.

The full report brings these relationships together in its buyer behaviour and geographic demand mapping chapters, which are summarised here only at category level.

One further implication is for geographic expansion. Patient group profiles differ by country, with some markets showing stronger geriatric demand and others a larger pediatric hospital sector, so the same product range may find different openings in different European markets.